{"id":"cm326","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL6068152","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CM326 binds to OX40 (CD134) on activated T cells, providing co-stimulatory signals that enhance T-cell proliferation, survival, and effector function. By agonizing OX40, the drug promotes anti-tumor immune responses and can be used as a monotherapy or in combination with other immunotherapies to overcome immune suppression in the tumor microenvironment.","oneSentence":"CM326 is a monoclonal antibody that targets and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:05.762Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT07420257","phase":"PHASE3","title":"A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis","status":"NOT_YET_RECRUITING","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2026-02-28","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":212},{"nctId":"NCT07418736","phase":"PHASE2","title":"A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-12-18","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":318},{"nctId":"NCT07372287","phase":"PHASE3","title":"A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma","status":"NOT_YET_RECRUITING","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2026-01-26","conditions":"Moderate to Severe Asthma","enrollment":230},{"nctId":"NCT05715333","phase":"PHASE1","title":"Study of CM326 Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2023-03-21","conditions":"Healthy","enrollment":46},{"nctId":"NCT05324137","phase":"PHASE1, PHASE2","title":"A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-07-11","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":88},{"nctId":"NCT06372678","phase":"PHASE2","title":"Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis","status":"NOT_YET_RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2024-06-30","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":90},{"nctId":"NCT05774340","phase":"PHASE2","title":"A Study of CM326 in Subjects With Moderate to Severe Asthma","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-05-18","conditions":"Moderate to Severe Asthma","enrollment":207},{"nctId":"NCT05671445","phase":"PHASE2","title":"The Study of CM326 in Adult Subjects With Atopic Dermatitis","status":"UNKNOWN","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2023-02-09","conditions":"Atopic Dermatitis","enrollment":100},{"nctId":"NCT05171348","phase":"PHASE1","title":"A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-01-07","conditions":"Asthma","enrollment":40},{"nctId":"NCT05671432","phase":"PHASE2","title":"The Study of CM326 in Moderate-to-severe Atopic Dermatitis","status":"UNKNOWN","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-12-27","conditions":"Moderate-to-severe Atopic Dermatitis","enrollment":240},{"nctId":"NCT04842201","phase":"PHASE1","title":"Single Ascending Dose Study of CM326 in Healthy Volunteers","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2021-04-13","conditions":"Asthma","enrollment":44},{"nctId":"NCT05186922","phase":"PHASE1, PHASE2","title":"The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis","status":"UNKNOWN","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2022-02-17","conditions":"Moderate-to-severe Atopic Dermatitis","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CM326","genericName":"CM326","companyName":"Keymed Biosciences Co.Ltd","companyId":"keymed-biosciences-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CM326 is a monoclonal antibody that targets and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}